Mulcahy AW, Hlavka JP, Case SR. Biosimilar cost savings in the United States: initial experience and future potential. Rand Health Q. 2018;7(4):3.
Zhai MZ, Sarpatwari A, Kesselheim AS. Why are biosimilars not living up to their promise in the US? AMA J Ethics. 2019;21(8):E668–78.
Cost Estimate. S. 1695: Biologics Price Competition and Innovation Act of 2007. Washington, DC: Congressional Budget Office. 2008.
Food and Drug Administration. FDA-Approved Biosimilar Products. https://www.fda.gov/drugs/biosimilars/biosimilar-product-information. Accessed 31 Jan 2021.
Herndon K, Braithwaite J, Berry B, Bourget K. Biosimilar perceptions among healthcare professionals and commercial medical benefit policy analysis in the United States. BioDrugs. 2021. https://doi.org/10.1007/s40259-020-00463-6.
IQVIA Institute for Human Data Science. Biosimilars in the United States 2020–2024. https://www.iqvia.com/-/media/iqvia/pdfs/institute-reports/iqvia-institute-biosimilars-in-the-united-states.pdf?_=1602260351753. Accessed 9 Oct 2020.
Sarnola K, Merikoski M, Jyrkka J, Hameen-Anttila K. Physicians’ perceptions of the uptake of biosimilars: a systematic review. BMJ Open. 2020;10(5):e034183. https://doi.org/10.1136/bmjopen-2019-034183.
Leonard E, Wascovich M, Oskouei S, Gurz P, Carpenter D. Factors affecting health care provider knowledge and acceptance of biosimilar medicines: a systematic review. J Manag Care Spec Pharm. 2019;25(1):102–12.
Barsell A, Rengifo-Pardo M, Ehrlich A. A survey assessment of US Dermatologists’ perception of biosimilars. J Drugs Dermatol. 2017;16(6):612–5.
Cohen H, Beydoun D, Chien D, Lessor T, McCabe D, Muenzberg M, et al. Awareness, knowledge, and perceptions of biosimilars among specialty physicians. Adv Ther. 2016;33(12):2160–72. https://doi.org/10.1007/s12325-016-0431-5.
Cook JW, McGrath MK, Dixon MD, Switchenko JM, Harvey RD, Pentz RD. Academic oncology clinicians’ understanding of biosimilars and information needed before prescribing. Ther Adv Med Oncol. 2019;11:1758835918818335. https://doi.org/10.1177/1758835918818335.
Cohen HP, McCabe D. The importance of countering biosimilar disparagement and misinformation. BioDrugs. 2020;34(4):407–14. https://doi.org/10.1007/s40259-020-00433-y.
Chambers JD, Lai RC, Margaretos NM, Panzer AD, Cohen JT, Neumann PJ. Coverage for biosimilars vs reference products among US Commercial Health Plans. JAMA. 2020;323(19):1972–3.
Yazdany J, Dudley RA, Lin GA, Chen R, Tseng C-W. Out-of-pocket costs for infliximab and its biosimilar for rheumatoid arthritis under Medicare Part D. JAMA. 2018;320(9):931–3.
Karaca-Mandic P, Chang J, Go R, Schondelmeyer S, Weisdorf D, Jeffery MM. Biosimilar filgrastim uptake and costs among commercially insured, Medicare Advantage. Health Aff (Millwood). 2019;38(11):1887–92. https://doi.org/10.1377/hlthaff.2019.00253.
Kozlowski S, Birger N, Brereton S, McKean SJ, Wernecke M, Christl LA, et al. Uptake of the biologic filgrastim and its biosimilar product among the medicare population. JAMA. 2018;320(9):929–31.
Chen AJ, Ribero R, Van Nuys K. Provider differences in biosimilar uptake in the filgrastim market. Am J Manag Care. 2020;26(5):208–13. https://doi.org/10.37765/ajmc.2020.42786.
Baker JF, Leonard CE, Lo Re V, Weisman MH, George MD, Kay J. Biosimilar uptake in academic and veterans health administration settings: influence of institutional incentives. Arthritis Rheumatol. 2020. https://doi.org/10.1002/art.41277.
Nonproprietary Naming of Biological Products: Guidance for Industry. FDA-2013-D-1543. Silver Spring: Food and Drug Administration. 2017.
Nonproprietary Naming of Biological Products: Update Guidance for Industry (Draft Guidance). FDA-2013-D-1543. Silver Spring: Food and Drug Administration. 2019.
Sarpatwari A, Barenie R, Curfman G, Darrow JJ, Kesselheim AS. The US biosimilar market: stunted growth and possible reforms. Clin Pharmacol Ther. 2019;105(1):92–100. https://doi.org/10.1002/cpt.1285.
Chang LC. The biosimilar pathway in the USA: An analysis of the innovator company and biosimilar company perspectives and beyond. J Food Drug Anal. 2019;27(3):671–8. https://doi.org/10.1016/j.jfda.2019.03.003.
Jordan JB, Christl L. FDA Biosimilar Action Plan: could improving pharmacovigilance of biologics improve patient and physician confidence in biosimilars? Expert Opin Drug Saf. 2020;19(3):229–32. https://doi.org/10.1080/14740338.2020.1733966.
O’Callaghan J, Bermingham M, Leonard M, Hallinan F, Morris JM, Moore U, et al. Assessing awareness and attitudes of healthcare professionals on the use of biosimilar medicines: a survey of physicians and pharmacists in Ireland. Regul Toxicol Pharmacol. 2017;88:252–61. https://doi.org/10.1016/j.yrtph.2017.06.013.
Chapman SR, Fitzpatrick RW, Aladul MI. Knowledge, attitude and practice of healthcare professionals towards infliximab and insulin glargine biosimilars: result of a UK web-based survey. BMJ Open. 2017;7(6):e016730. https://doi.org/10.1136/bmjopen-2017-016730.
Baji P, Gulacsi L, Golovics PA, Lovasz BD, Pentek M, Brodszky V, et al. Perceived risks contra benefits of using biosimilar drugs in ulcerative colitis: discrete choice experiment among gastroenterologists. Value Health Reg Issues. 2016;10:85–90. https://doi.org/10.1016/j.vhri.2016.07.004.